blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1558222

EP1558222 - PHARMACEUTICAL COMPOSITIONS CONTAINING VENLAFAXINE [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  10.08.2012
Database last updated on 16.07.2024
Most recent event   Tooltip10.08.2012Application deemed to be withdrawnpublished on 12.09.2012  [2012/37]
Applicant(s)For all designated states
Dexcel Pharma Technologies Ltd.
P.O. Box 23950
91237 Jerusalem / IL
[2005/31]
Inventor(s)01 / PENHASI, Adel
53/15 Rabinovich Street
IL-58671 Holon / IL
02 / GOMBERG, Mila
608/8 Victor and Julius Street
IL-97482 Jerusalem / IL
03 / AVRAMOFF, Avi
26 Lea Street
IL-34405 Haifa / IL
 [2005/31]
Representative(s)Schrell, Andreas, et al
Gleiss Grosse Schrell und Partner mbB
Patentanwälte Rechtsanwälte
Leitzstrasse 45
70469 Stuttgart / DE
[N/P]
Former [2005/31]Schrell, Andreas, Dr., et al
Gleiss Grosse Schrell & Partner Patentanwälte Rechtsanwälte Leitzstrasse 45
70469 Stuttgart / DE
Application number, filing date03758627.823.10.2003
[2005/31]
WO2003IL00862
Priority number, dateUS2002028008425.10.2002         Original published format: US 280084
IL2003015849320.10.2003         Original published format: IL 15849303
[2005/31]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2004037226
Date:06.05.2004
Language:EN
[2004/19]
Type: A2 Application without search report 
No.:EP1558222
Date:03.08.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 06.05.2004 takes the place of the publication of the European patent application.
[2005/31]
Search report(s)International search report - published on:EP08.07.2004
ClassificationIPC:A61K9/28, A61K31/137
[2005/31]
CPC:
A61K31/135 (EP); A61K9/2866 (EP); C07C217/74 (EP);
C07C2601/14 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/31]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ENTHALTEND VENLAFAXINE[2005/31]
English:PHARMACEUTICAL COMPOSITIONS CONTAINING VENLAFAXINE[2005/31]
French:COMPOSITIONS PHARMACEUTIQUES RENFERMANT DE LA VENLAFAXINE[2005/31]
Entry into regional phase25.05.2005National basic fee paid 
25.05.2005Designation fee(s) paid 
25.05.2005Examination fee paid 
Examination procedure25.05.2005Examination requested  [2005/31]
09.11.2011Despatch of a communication from the examining division (Time limit: M04)
20.03.2012Application deemed to be withdrawn, date of legal effect  [2012/37]
25.04.2012Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2012/37]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  09.11.2011
Fees paidRenewal fee
12.10.2005Renewal fee patent year 03
12.10.2006Renewal fee patent year 04
12.10.2007Renewal fee patent year 05
14.10.2008Renewal fee patent year 06
13.10.2009Renewal fee patent year 07
25.10.2010Renewal fee patent year 08
20.10.2011Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[DA]US6274171  (SHERMAN DEBORAH M ET AL) [DA] 1-88 * examples 1-7; claims 1,20-25 *;
 [A]US2001048943  (VERGEZ JUAN ET AL) [A] 1-88 * paragraphs [0042] , [0047] , [0048] , [0052] * * examples 1-5 * * claims 1,5 *;
 [PA]WO03055475  (LEK TOVARNA FARMACEVTSKIH ;JANEZ KERC (SL); VLASTA HUMAR (SL)) [PA] 1-88 * page 2, paragraphs 3,4 * * examples 1-5 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.